John Doyle

John Doyle was chief executive officer and a member of the board of directors at Castlight Health, a publicly held healthcare IT firm, from 2017 to 2019. John joined Castlight in 2012 as its chief financial officer and held that role through the Company’s initial public offering. He was later named chief operating officer and then president of the Company in 2016. Prior to joining Castlight, John was chief operating officer of Achaogen, Inc., a biotechnology company focused on the development of antibiotics for the treatment of life-threatening infections. He joined Achaogen in 2009 and also served as chief financial officer in addition to his role as COO. Upon leaving Achaogen to join Castlight in 2012, John was named to the board of Achaogen where he served until 2019. As a member of the Achaogen board, John served at various times as chairperson of the compensation committee and as a member of the nominating and governance committee. Prior to joining Achaogen, John was vice president of corporate finance and business planning at Genentech from 2007 until 2009 when Genentech became a wholly owned subsidiary of Roche. Prior to Genentech, John spent more than 15 years primarily in the biotechnology industry where he had most recently been the senior vice president of corporate development and chief financial officer of Renovis, a publicly held biotechnology firm. John holds an MBA from the University of California, Berkeley, and received his undergraduate degree from California Polytechnic State University, San Luis Obispo. He is a member of the 2012 Class of Henry Crown Fellows at the Aspen Institute.